Cargando…

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

BACKGROUND: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with advanced HCC and Child–Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feun, Lynn G, Wangpaichitr, Medhi, Li, Ying-Ying, Kwon, Deukwoo, Richman, Stephen P, Hosein, Peter J, Savaraj, Niramol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769585/ https://www.ncbi.nlm.nih.gov/pubmed/29392123 http://dx.doi.org/10.2147/JHC.S153672

Ejemplares similares

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
por: Wu, Chunjing, et al.
Publicado: (2021)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

N′(1),N′(3)-Dimethyl-N′(1),N′(3)-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)
por: Wangpaichitr, Medhi, et al.
Publicado: (2009)

Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor
por: Wangpaichitr, Medhi, et al.
Publicado: (2002)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
por: Wangpaichitr, Medhi, et al.
Publicado: (2021)

Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy
por: Li, Ying-Ying, et al.
Publicado: (2017)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
por: Li, Ying‐Ying, et al.
Publicado: (2017)

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer
por: Wangpaichitr, Medhi, et al.
Publicado: (2017)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
por: Wolin, Edward M., et al.
Publicado: (2013)

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
por: Golor, Georg, et al.
Publicado: (2012)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know
por: Bhatia, Shivank, et al.
Publicado: (2016)

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
por: Kuo, Macus Tien, et al.
Publicado: (2010)

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
por: Wu, Chunjing, et al.
Publicado: (2023)

Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy
por: Kuo, Macus Tien, et al.
Publicado: (2021)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
por: Rouland, Alexia, et al.
Publicado: (2021)

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation
por: Long, Yan, et al.
Publicado: (2016)

Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
por: Kuo, Macus Tien, et al.
Publicado: (2019)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization
por: Lanza, Ezio, et al.
Publicado: (2020)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts
por: Moatassim-Billah, Siham, et al.
Publicado: (2016)

Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer
por: Wangpaichitr, M, et al.
Publicado: (2017)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression
por: Tsai, Wen-Bin, et al.
Publicado: (2017)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study
por: Benamouzig, Robert, et al.
Publicado: (2018)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Fysikåret som gått
Publicado: (2008)

ShinySOM: graphical SOM-based analysis of single-cell cytometry data
por: Kratochvíl, Miroslav, et al.
Publicado: (2020)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kgminedpeb6v9afbrsa6jr0jdn